WO2000041473A3 - Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections - Google Patents

Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections Download PDF

Info

Publication number
WO2000041473A3
WO2000041473A3 PCT/EP2000/000165 EP0000165W WO0041473A3 WO 2000041473 A3 WO2000041473 A3 WO 2000041473A3 EP 0000165 W EP0000165 W EP 0000165W WO 0041473 A3 WO0041473 A3 WO 0041473A3
Authority
WO
WIPO (PCT)
Prior art keywords
infections
treatment
isoxazolidinones
hydroxylamine
acids
Prior art date
Application number
PCT/EP2000/000165
Other languages
German (de)
English (en)
Other versions
WO2000041473A2 (fr
Inventor
Hassan Jomaa
Original Assignee
Jomaa Pharmaka Gmbh
Hassan Jomaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19903666A external-priority patent/DE19903666A1/de
Priority to EA200100768A priority Critical patent/EA200100768A1/ru
Priority to BR0007491-8A priority patent/BR0007491A/pt
Priority to EP00902582A priority patent/EP1143941A3/fr
Priority to IL14379500A priority patent/IL143795A0/xx
Priority to SK950-2001A priority patent/SK9502001A3/sk
Application filed by Jomaa Pharmaka Gmbh, Hassan Jomaa filed Critical Jomaa Pharmaka Gmbh
Priority to AU24366/00A priority patent/AU2436600A/en
Priority to CA002360366A priority patent/CA2360366A1/fr
Priority to JP2000593097A priority patent/JP2002534440A/ja
Publication of WO2000041473A2 publication Critical patent/WO2000041473A2/fr
Priority to NO20013464A priority patent/NO20013464L/no
Publication of WO2000041473A3 publication Critical patent/WO2000041473A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des médicaments contenant au moins un composé de formule générale (I), ainsi que leur utilisation pour le traitement thérapeutique et prophylactique d'infections chez l'homme et chez les animaux, provoquées par des bactéries, champignons et parasites.
PCT/EP2000/000165 1999-01-13 2000-01-12 Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections WO2000041473A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2000593097A JP2002534440A (ja) 1999-01-13 2000-01-12 感染症の治療のための３−イソキサゾリジノンおよびヒドロキシルアミン酸の使用
BR0007491-8A BR0007491A (pt) 1999-01-13 2000-01-12 Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
EP00902582A EP1143941A3 (fr) 1999-01-13 2000-01-12 Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections
IL14379500A IL143795A0 (en) 1999-01-13 2000-01-12 Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections
SK950-2001A SK9502001A3 (en) 1999-01-13 2000-01-12 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
EA200100768A EA200100768A1 (ru) 1999-01-13 2000-01-12 Применение 3-изоксазолидинонов и гидроксиаминокислот для лечения инфекций
AU24366/00A AU2436600A (en) 1999-01-13 2000-01-12 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
CA002360366A CA2360366A1 (fr) 1999-01-13 2000-01-12 Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections
NO20013464A NO20013464L (no) 1999-01-13 2001-07-12 Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19900907.4 1999-01-13
DE19900907 1999-01-13
DE19903666A DE19903666A1 (de) 1999-01-13 1999-01-30 Arzneimittel mit einem Gehalt an 3-Isoxazolidinonen und Hydroxylaminsäuren als Wirkstoff und ihre Verwendung
DE19903666.7 1999-01-30

Publications (2)

Publication Number Publication Date
WO2000041473A2 WO2000041473A2 (fr) 2000-07-20
WO2000041473A3 true WO2000041473A3 (fr) 2001-11-29

Family

ID=26051290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000165 WO2000041473A2 (fr) 1999-01-13 2000-01-12 Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections

Country Status (14)

Country Link
EP (1) EP1143941A3 (fr)
JP (1) JP2002534440A (fr)
CN (1) CN1342078A (fr)
AU (1) AU2436600A (fr)
BR (1) BR0007491A (fr)
CA (1) CA2360366A1 (fr)
CZ (1) CZ20012380A3 (fr)
HU (1) HUP0105412A2 (fr)
IL (1) IL143795A0 (fr)
NO (1) NO20013464L (fr)
PL (1) PL350128A1 (fr)
SK (1) SK9502001A3 (fr)
TR (1) TR200102019T2 (fr)
WO (1) WO2000041473A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443930A1 (fr) 2001-10-25 2004-08-11 AstraZeneca AB Derives d'isoxazoline utilises en tant qu'agents antimicrobiens
GB202209172D0 (en) * 2022-06-22 2022-08-10 Syngenta Crop Protection Ag Improvements in or relating to organic compounds

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911007A (en) * 1974-08-08 1975-10-07 Searle & Co N-substituted N-benzyloxy-2-methyl-2-(4-halophenoxy)propionamides
FR2290442A1 (fr) * 1974-11-06 1976-06-04 Aries Robert Nouvelles rifamycines
GB1457950A (en) * 1973-08-10 1976-12-08 Merck & Co Inc Antibacterial compositions
WO1987004152A1 (fr) * 1985-12-30 1987-07-16 The Wellcome Foundation Ltd. Nouveaux derives aryles
JPS63119462A (ja) * 1986-11-05 1988-05-24 Takeda Chem Ind Ltd 五員環ｎ−スルホ化合物
JPS63119476A (ja) * 1986-11-05 1988-05-24 Takeda Chem Ind Ltd イソキサゾリドン誘導体
US4851422A (en) * 1985-04-30 1989-07-25 Takeda Chemical Industries, Ltd. Antibiotic 2-(3-oxo-2-isoxazolidinyl)-5-oxo-2-tetrahydrofuran-carboxylates
US5288896A (en) * 1992-01-15 1994-02-22 Warner-Lambert Company 3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
WO1995006031A1 (fr) * 1993-08-23 1995-03-02 Immunex Corporation Inhibiteurs de la secretion de facteur alpha de necrose tumorale
WO1995019957A1 (fr) * 1994-01-21 1995-07-27 British Biotech Pharmaceuticals Limited Derives d'acide hydroxamique inhibiteurs de metalloproteinase
WO1996013263A2 (fr) * 1994-11-01 1996-05-09 Research Corporation Technologies, Inc. Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides
US5652262A (en) * 1993-03-16 1997-07-29 British Biotech Pharmaceutical, Ltd. Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1998043959A1 (fr) * 1997-03-28 1998-10-08 Zeneca Limited Acides hydroxamiques substitues par des composes heterocycliques pouvant inhiber le facteur de necrose tumorale
WO1998055449A1 (fr) * 1997-06-06 1998-12-10 The University Of Queensland Composes d'acide hydroxamique ayant des proprietes anticancereuses et antiparasitaires
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457950A (en) * 1973-08-10 1976-12-08 Merck & Co Inc Antibacterial compositions
US3911007A (en) * 1974-08-08 1975-10-07 Searle & Co N-substituted N-benzyloxy-2-methyl-2-(4-halophenoxy)propionamides
FR2290442A1 (fr) * 1974-11-06 1976-06-04 Aries Robert Nouvelles rifamycines
US4851422A (en) * 1985-04-30 1989-07-25 Takeda Chemical Industries, Ltd. Antibiotic 2-(3-oxo-2-isoxazolidinyl)-5-oxo-2-tetrahydrofuran-carboxylates
WO1987004152A1 (fr) * 1985-12-30 1987-07-16 The Wellcome Foundation Ltd. Nouveaux derives aryles
JPS63119476A (ja) * 1986-11-05 1988-05-24 Takeda Chem Ind Ltd イソキサゾリドン誘導体
JPS63119462A (ja) * 1986-11-05 1988-05-24 Takeda Chem Ind Ltd 五員環ｎ−スルホ化合物
US5288896A (en) * 1992-01-15 1994-02-22 Warner-Lambert Company 3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
US5652262A (en) * 1993-03-16 1997-07-29 British Biotech Pharmaceutical, Ltd. Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1995006031A1 (fr) * 1993-08-23 1995-03-02 Immunex Corporation Inhibiteurs de la secretion de facteur alpha de necrose tumorale
WO1995019957A1 (fr) * 1994-01-21 1995-07-27 British Biotech Pharmaceuticals Limited Derives d'acide hydroxamique inhibiteurs de metalloproteinase
WO1996013263A2 (fr) * 1994-11-01 1996-05-09 Research Corporation Technologies, Inc. Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1998043959A1 (fr) * 1997-03-28 1998-10-08 Zeneca Limited Acides hydroxamiques substitues par des composes heterocycliques pouvant inhiber le facteur de necrose tumorale
WO1998055449A1 (fr) * 1997-06-06 1998-12-10 The University Of Queensland Composes d'acide hydroxamique ayant des proprietes anticancereuses et antiparasitaires

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BALDWIN, JACK E. ET AL: "Synthesis of phenoxyacetyl-N-sulfonyl cycloserine", TETRAHEDRON LETT. (1987), 28(37), 4319-20, 1987, XP000990044 *
BALDWIN, JACK E. ET AL: "The synthesis of potential.gamma.-lactam antibiotics containing a cycloserine nucleus", TETRAHEDRON LETT. (1990), 31(15), 2211-12, 1990, XP000990045 *
GEARY, TIMOTHY G. ET AL: "Nutritional requirements of Plasmodium falciparum in culture. II. Effects of antimetabolites in a semi-defined medium", J. PROTOZOOL. (1985), 32(1), 65-9, 1985, XP000952017 *
GERARDIN, PHILIPPE ET AL: "Synthesis of potential.gamma.-lactam antibiotics", BIOORG. MED. CHEM. LETT. (1995), 5(14), 1467-70, 1995, XP004135426 *
KHALIL, ZARIF HALEEM ET AL: "Synthesis and application of some 1-[8-hydroxy-5(or 7)-quinolinyl]alkylidene-substituted heterocycles as bactericides, fungicides, and bioregulators", BULL. CHEM. SOC. JPN. (1988), 61(4), 1345-9, 1988, XP000990042 *
MITTENDORF, JOACHIM: "Enantioselective synthesis of (R)- and (S)-4-methylcycloserine by the bislactim ether method", LIEBIGS ANN. CHEM. (1988), (12), 1201-2, 1988, XP000990041 *
NICHTERLEIN, THOMAS ET AL: "Subinhibitory concentrations of.beta.-lactams and other cell-wall antibiotics inhibit listeriolysin production by Listeria monocytogenes", INT. J. ANTIMICROB. AGENTS (1996), 7(1), 75-81, 1996, XP000991436 *
O'GRADY, F.: "Cycloserine, amino acid analogs and oligopeptides", ANTIBIOT. CHEMOTHER. (7TH ED.) (1997), 344-345. EDITOR(S): O'GRADY, FRANCIS. PUBLISHER: CHURCHILL LIVINGSTONE, EDINBURGH, UK., 1997, XP000951569 *
OMAR, M. T.: "Synthesis of some new isoxazolidine-3,5-diones, pyrazolidine-3,5- diones, and barbituric acids of expected antimicrobial activity", EGYPT. J. PHARM. SCI. (1998), VOLUME DATE 1997, 38(4-6), 281-289, 1998, XP000991461 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 365 (C - 532) 29 September 1988 (1988-09-29) *
STAMMER, CHARLES H. ET AL: "5-Carboxamido-4-amino-3-isoxazolidone, an asparagine analog", J. MED. CHEM. (1978), 21(7), 709-12, 1978, XP000990040 *
TAMURA, NORIKAZU ET AL: "Synthesis and antibacterial activity of lactivicin derivatives", CHEM. PHARM. BULL. (1990), 38(1), 116-22, 1990, XP000990010 *
UEDA, Y. ET AL: "Synthesis of phenoxyacetyl-N-(hydroxydioxocyclobutenyl)cycloserines", TETRAHEDRON LETT. (1991), 32(31), 3767-70, 1991, XP000990046 *
VIGORITA, M. GABRIELLA ET AL: "Fluoro-containing D-cycloserines. Synthesis and in vitro evaluation of antimicrobial and antiviral activities", FARMACO (1992), 47(6), 907-18, 1992, XP000991416 *
WEWALKA, G. ET AL: "Sensitivity of bacteria causing urinary tract infections towards Terizidone", WIEN. KLIN. WOCHENSCHR. (1976), 88(11), 355-60, 1976, XP000991442 *
WISE, R. ET AL: "In vitro activity of fludalanine combined with pentizidone compared with those of other agents", ANTIMICROB. AGENTS CHEMOTHER. (1984), 25(5), 612-17, 1984, XP000991424 *

Also Published As

Publication number Publication date
CA2360366A1 (fr) 2000-07-20
NO20013464L (no) 2001-09-12
CN1342078A (zh) 2002-03-27
EP1143941A2 (fr) 2001-10-17
CZ20012380A3 (cs) 2002-01-16
HUP0105412A2 (hu) 2002-05-29
PL350128A1 (en) 2002-11-04
TR200102019T2 (tr) 2002-04-22
EP1143941A3 (fr) 2002-02-06
JP2002534440A (ja) 2002-10-15
BR0007491A (pt) 2001-11-20
AU2436600A (en) 2000-08-01
WO2000041473A2 (fr) 2000-07-20
SK9502001A3 (en) 2002-05-09
NO20013464D0 (no) 2001-07-12
IL143795A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
WO2003010138A3 (fr) Medicaments
WO2001007432A3 (fr) Composes
MXPA04012965A (es) Inhibidores virales.
WO2004058144A3 (fr) Agents antibacteriens
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO1999052515A3 (fr) Utilisation de liaisons organophosphorees dans le traitement et la prevention d'infections
ZA200202306B (en) Topical treatment of streptococcal infections.
WO2004041210A3 (fr) Agents antibacteriens
WO2001045679A3 (fr) Utilisation d'agents chimiotherapeutiques
EP1247456A3 (fr) Compositions pharmaceutiques savoureux pour les animaux domestiques
MY125356A (en) Moxifloxacin/sodium chloride formulation
AU2119200A (en) Medicament
WO2004096982A3 (fr) Agents antibacteriens
WO1999063978A3 (fr) Methodes de traitement de l'infection microbienne et formulations therapeutiques prevues a cet effet
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
CA2368165A1 (fr) Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie
CA2267309A1 (fr) Utilisation de 1-hydroxy-2-pyridones pour le traitement d'infections cutanees
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
WO2003009859A1 (fr) Immunotherapie pour humains
WO2004039822A3 (fr) Composes
WO2002053149A3 (fr) Medicaments contenant une polyamine en tant que principe actif
WO2002000208A3 (fr) Preparations de derives d'acide 3-n-formylhydroxylaminopropylphosphonique ou de derives d'acide 3-n-acetylhydroxylaminopropylphosphonique combines avec des principes actifs pharmaceutiques speciaux
CA2386685A1 (fr) Utilisation de derives de pleuromutiline pour le traitement transdermique de maladies bacteriennes
EP1114826A3 (fr) Macrolides antibactériennes et prokinétiques
WO2003024996A3 (fr) Macrocycles antibacteriens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00802779.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 143795

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001/05007

Country of ref document: ZA

Ref document number: 200105007

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00746/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2001-2380

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 24366/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09869738

Country of ref document: US

Ref document number: 9502001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2001/02019

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2360366

Country of ref document: CA

Ref document number: 2360366

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 593097

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000902582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200100768

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2000902582

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: PV2001-2380

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-2380

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000902582

Country of ref document: EP